Drug intelligence / Profile preview

CT-03

Development stage: Preclinical
Lead developer: Captor Therapeutics
Modality: Small Molecules

Overview

CT-03 is a preclinical drug candidate developed by Captor Therapeutics SA. It functions as an Mcl-1 degrader, targeting the Induced myeloid leukemia cell differentiation protein Mcl-1. By inducing the degradation of this key anti-apoptotic protein, CT-03 aims to promote programmed cell death in cancer cells. It is currently being investigated for its potential therapeutic use in various neoplasms, including hematologic neoplasms and solid tumors.

Other names: MCL-1 bi-functional degraderMCL1 bi-functional degraderMCL 1 bi-functional degraderMCL-1 programMCL1 programMCL 1 program

Targets

MCL1 (Myeloid cell leukemia sequence 1)

Beyond the preview

Go deeper on CT-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-03.

Explore the full profile